Brazil Just Raised Taxes on Medical Devices. Here's Why That Changes Everything.

In February 2026, Brazil's government quietly changed the tax structure for medical devices.

The measure—GECEX Resolution 852/26—increased import taxes on machines, equipment, and IT products used in healthcare.

On the surface, it looked like a technical adjustment.

In practice, it's creating a crisis that hospitals, manufacturers, and patients are only starting to understand.

The Numbers Don't Lie

That's not a choice. It's reality.

According to data from Redirection International, approximately one-third of medical devices come from national production, while the rest is imported—positioning Brazil among the ten largest markets in the world but deeply dependent on international supply.

The market moved approximately R$ 75 billion in 2025.

And between January and August 2025, medical device imports totaled US$ 7.23 billion, a growth of 8.37% compared to the same period in 2024.

These aren't luxury items. They're diagnostic imaging systems, sterilization equipment, hospital climate control, laboratory instruments—technologies Brazil doesn't produce domestically.

Which brings us to the problem.

The Logic That Doesn't Make Sense

He said this during a public hearing at Brazil's Chamber of Deputies on April 14, 2026, and the statement cuts straight to the core of the issue.

If Brazil had a domestic industry capable of replacing these imports, the policy might make strategic sense.

But it doesn't.

So what's actually happening?

Hospitals are paying more. Patients are waiting longer. And the SUS—Brazil's public health system—is absorbing costs it can't sustain.

The Real Impact: 11% Cost Increase

Genildo Lins, executive director of the National Health Confederation (CNSaúde), estimated that laboratories and hospitals will face costs up to 11% higher.

That's not just a number on a spreadsheet.

Graccho Alvim Neto, vice-president of the Brazilian Federation of Hospitals (FBH), emphasized that the change primarily affects small and medium-sized facilities, potentially causing delays in exams and surgeries.

And here's what makes it worse.

The problem with the resolution was the process: there was no public hearing, entities weren't consulted, and there was no regulatory impact analysis, according to Lins.

The industry wasn't prepared. Hospitals weren't prepared. And the financial impact is already being felt.

How This Reaches the SUS

Many assume this only affects private hospitals.

It doesn't.

Renato Nunes, legal consultant for the National Association of Private Hospitals (Anahp), explained that increased costs reach the SUS through philanthropic hospitals that purchase materials from national resellers who pay the tax, elevating the final cost.

These entities play a critical role in the SUS network.

When their costs go up, service capacity goes down.

The burden doesn't stop at the institution—it reaches the population.

The Question Every Manufacturer's Asking

If you're a foreign manufacturer entering Brazil—or already operating here—this creates an immediate problem.

Your products just became 11% more expensive to deliver.

Your distributors are facing margin pressure.

Your hospital customers are re-evaluating purchases.

And your competitive position just weakened—not because of your product, but because of a policy change you couldn't predict.

So what do you do?

There's a Legal Way to Navigate This

Here's what most manufacturers don't realize:

The challenge isn't the tax itself. It's how importation and distribution are organized.

Most companies follow a traditional model:

Appoint a distributor → transfer registration → distributor imports → markup gets added at every layer → hospital pays inflated price.

But there's another model.

One where manufacturers maintain control of the registration, work through an integrated regulatory and importation structure, and leverage tax optimization strategies that are fully compliant with Brazilian law.

The result?

Products reach hospitals at significantly lower costs—even with the new tax increase.

What Strategic Tax Planning Actually Looks Like

When done correctly, manufacturers can:

Reduce landed costs despite higher taxes.
Maintain pricing competitiveness without sacrificing margins.
Increase hospital access by making products more affordable.
Stay fully compliant with ANVISA, Receita Federal, and all regulatory requirements.

And this matters now more than ever.

The Model That's Already Working

Some manufacturers entering Brazil are structuring their operations differently from the start.

They're working with platforms that combine regulatory support, tax optimization, and direct market access—eliminating the traditional layers that drive up costs.

One example's the gropo model—a digital procurement platform designed specifically for this challenge.

It connects manufacturers directly to hospitals and GPOs through an integrated structure that includes:

Brazil Registration Hosting Service (BRHS) through BIHS
Strategic tax planning
Collective purchasing power
Direct distribution coordination

The result isn't just compliance.

It's cost reduction at a time when every percentage point matters.

Why This Matters Right Now

The tax increase is already in effect.

Hospitals are already adjusting budgets.

Procurement teams are already re-evaluating suppliers.

And manufacturers who can demonstrate cost-competitive solutions—despite the new taxes—are winning contracts.

The opportunity isn't avoiding the tax.

It's structuring the operation so the tax doesn't eliminate your competitive position.

A Conversation Worth Having

If you're entering Brazil—or already here and feeling the impact of Resolution 852/26—it's worth understanding how strategic structuring can offset these changes.

Because in a market where two-thirds of products are imported and costs just went up 11%, the companies that succeed won't be the ones who accept the new reality.

They'll be the ones who restructure around it.